GERN at a glance
GERON CORP (GERN, SEC CIK 886744) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding GERON CORP (GERN) shares worth $250.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Williams Timothy on November 16, 2026 of 12,000 shares at $0.94 per share.
- In the last 90 days, GERN insiders reported 2 open-market purchases ($62K) and 0 open-market sales ($0) on Form 4, a net purchase of $62K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$62K
- 13F holders
- 28 funds
- $250.8M · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Biopharmaceutical company focused on cancer therapeutics development
- No new products, services, or segments introduced or emphasized in this filing year
- Continued emphasis on corporate governance with established Code of Conduct and Insider Trading Policy
- No quantitative metrics disclosed in Business section; governance details referenced extensively to Proxy Statement
- Unusual fact: Entire Business section replaced by governance, ethics, and reference to Proxy Statement, lacking typical operational details
Risk Factors
- Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation
- Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations
- Supply chain risk: $60 million in manufacturing commitments for RYTELO requiring long lead-times and incurring cancellation penalties
- Competitive risk: Potential market disruption if RYTELO commercialization fails or competitors advance alternative myelodysplastic syndrome treatments
- Financial risk: $119.5 million long-term debt principal with covenants and maturity in 2029, plus $141 million net proceeds dilution risk from equity offerings
Management Discussion & Analysis
- Risks focus on commercialization, regulatory approvals, clinical trial outcomes, manufacturing, and market acceptance of RYTELO (imetelstat)
- Forward-looking risks include FDA/EC approval timelines, clinical trial delays, competitive pressures, and macroeconomic impacts on operations
AI summary of the GERN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly triggered clinical-development risk: IMpactMF Phase 3 discontinued in October 2026 after an independent DMC found overall survival endpoint unlikely
- Most material commercial update: RYTELO revenue $169.4 million vs $135.6 million for nine months ended September 30, 2026 and 2025, respectively
- Regulatory risk: FDA and EU approvals require long-term safety studies and alternative-dosing trials, with potential penalties or withdrawal for noncompliance
- Near-term market risk: revised U.S. strategy targets high-volume earlier-line accounts and non-personal promotion after sales growth remained limited
- Financial risk: $125.0 million Pharmakon term loan secured by substantially all assets, including intellectual property, with Tranche B and C no longer available
Management Discussion & Analysis
- Q3 revenue $60.2M, up $13.0M YoY from $47.2M, driven by RYTELO product revenue
- Net income $1.4M vs $18.4M loss YoY, operating margin 9.6% vs (29.4)%
- RYTELO product revenue $60.1M, up $12.9M YoY, the only disclosed product line
- Cash, equivalents, restricted cash and securities $339.4M vs $401.1M at December 31, 2025
- Outlook: Germany availability expected by end-2026, Q4 gross-to-net adjustments expected in low to mid-twenties percentage range
AI summary of the GERN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Q3 2026 results for the quarter ended September 30, 2026
- Business highlights included alongside quarterly financial results, with investor detail in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 RYTELO revenue $60.1M, up 5% sequentially and 27% year over year, signaling continued commercial adoption in LR-MDS
- 2026 RYTELO revenue guidance maintained at mid-to-high end of $220M-$240M, while operating expense guidance reduced to $220M-$230M
Item 8.01: Other Events
- Geron issued a Phase 3 IMpactMF trial update for imetelstat in JAK inhibitor relapsed/refractory myelofibrosis
- Clinical update may materially affect imetelstat approval prospects, development timelines, and Geron’s valuation
Item EX-99.1: Item EX-99.1
- Phase 3 IMpactMF discontinued after independent DMC judged overall-survival endpoint unlikely to be met
- Trial enrolled 327 relapsed/refractory myelofibrosis patients after JAK-inhibitor treatment
Item EX-99.1: Item EX-99.1
- Q2 RYTELO revenue $57.5M, up 17% YoY and 11% sequentially, supporting continued commercial adoption
- Ordering accounts increased 8% to approximately 1,575, while demand rose 5% sequentially
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Business highlights included in Exhibit 99.1 press release
AI summaries of GERN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GERN
Don't miss the next GERN filing
- Alerts as it files. A push when GERN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GERN, by share count.
- Ask anything. An AI agent that reads every GERN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Williams Timothy | Buy | Nov 16, 2026 | 12,000 | $0.94 |
| Semerjian Harout | Buy | Nov 13, 2026 | 53,500 | $0.95 |
| Spiegel Robert J. | A | Sep 30, 2026 | 6,351 | $1.23 |
| Spiegel Robert J. | A | Jun 30, 2026 | 6,103 | $1.28 |
| McDonald John F | A | May 20, 2026 | 220,000 | - |
| Bir Dawn Carter | A | May 20, 2026 | 220,000 | - |
| O'Farrell Elizabeth G. | A | May 20, 2026 | 220,000 | - |
| Molineaux Susan | A | May 20, 2026 | 220,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$193.9M | -$173.7M | -$68.6M |
| Net Income | -$184.1M | -$174.6M | -$83.5M |
| Balance Sheet | |||
| Total Assets | $394.1M | $593.8M | $570.5M |
| Equity | $247.9M | $280.3M | $225.9M |
| ROE | -74.3% | -62.3% | -37.0% |
| Per Share | |||
| EPS | $-0.32 | $-0.27 | $-0.13 |
| Cash Flow | |||
| Operating CF | -$167.7M | -$218.6M | -$111.0M |
| CapEx | $830K | $680K | - |
Source: XBRL data in GERON CORP (GERN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate GERN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $250.8M |
| Q2 2026 | 30 | $281.3M |
| Q1 2026 | 29 | $279.2M |
| Q4 2025 | 26 | $233.8M |
| Q3 2025 | 26 | $265.4M |
| Q2 2025 | 24 | $251.6M |
| Q1 2025 | 23 | $218.0M |
| Q4 2024 | 20 | $360.5M |
- Two Sigma Investments+2.12M (+49%)
- Bank of America Corp+2.01M (+57%)
- BlackRock+1.45M (+3%)
- Franklin Resources+880.6K (+142%)
- Vanguard Capital Management LLC+422.0K (+2%)
- Citadel Advisors LLC−4.74M (-16%)
- State Street Corp−3.96M (-11%)
- Millennium Management−3.65M (-45%)
- Goldman Sachs Group−3.57M (-21%)
- Morgan Stanley−383.3K (-3%)
- FMR LLC (Fidelity)−5.50M
- AQR Capital Management−55.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GERN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | May 27, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 14, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 8-K | Mar 26, 2026 | - | - | - |
| 4 | Mar 26, 2026 | - | - | - |
| 4 | Mar 26, 2026 | - | - | - |
| SC 13G | Mar 3, 2026 | - | - | |
| 10-K | Mar 2, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 25, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GERN SEC filings: frequently asked questions
Are GERN insiders buying or selling?
In the last 90 days, GERON CORP (GERN) officers, directors and 10% owners reported 2 open-market purchases worth $62,105 by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold GERN stock?
As of September 30, 2026, the largest GERON CORP (GERN) holders among the 13F filers tracked by SignalX were BlackRock ($62.2 million), State Street Corp ($39.2 million), Vanguard Capital Management LLC ($34.0 million), Citadel Advisors LLC ($29.9 million), Goldman Sachs Group ($16.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in GERN's latest 10-K?
In the 10-K filed March 2, 2026, GERON CORP (GERN) flagged: Regulatory risk: Uncertainty in RYTELO approval beyond U.S. FDA and EU marketing authorization, affecting future launch timing and revenue generation. Macroeconomic risk: Exposure to inflation, trade tensions, interest rate fluctuations, and global crises impacting financing and operations. (AI summary of the Risk Factors section.)
What did GERN report in its latest 8-K?
GERON CORP (GERN) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Q3 2026 results for the quarter ended September 30, 2026.
What are the latest GERN SEC filings?
GERON CORP (GERN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 16, 2026.
What is GERN's SEC CIK number?
GERON CORP (GERN)'s SEC Central Index Key (CIK) is 886744. EDGAR lists every GERN filing under that number.
Ask anything about GERN
The research agent reads GERN's filings, financials, insider trades and 13F holders, then answers with sources.